1076 related articles for article (PubMed ID: 28666775)
1. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Tuttle KR; Hauske SJ; Canziani ME; Caramori ML; Cherney D; Cronin L; Heerspink HJL; Hugo C; Nangaku M; Rotter RC; Silva A; Shah SV; Sun Z; Urbach D; de Zeeuw D; Rossing P;
Lancet; 2024 Jan; 403(10424):379-390. PubMed ID: 38109916
[TBL] [Abstract][Full Text] [Related]
4. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
Zinman B; Inzucchi SE; Lachin JM; Wanner C; Ferrari R; Fitchett D; Bluhmki E; Hantel S; Kempthorne-Rawson J; Newman J; Johansen OE; Woerle HJ; Broedl UC
Cardiovasc Diabetol; 2014 Jun; 13():102. PubMed ID: 24943000
[TBL] [Abstract][Full Text] [Related]
5. Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.
Nangaku M; Herrington WG; Goto S; Maruyama S; Kashihara N; Ueki K; Wada J; Watada H; Nakashima E; Lee R; Massey D; Mayne KJ; Tomita A; Haynes R; Hauske SJ; Kadowaki T
Clin Exp Nephrol; 2024 Jun; 28(6):588-595. PubMed ID: 38643286
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial.
Hadjadj S; Cooper ME; Steubl D; Petrini M; Hantel S; Mattheus M; Wanner C; Thomas MC
Kidney Med; 2024 Mar; 6(3):100783. PubMed ID: 38419787
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
Groop PH; Cooper ME; Perkovic V; Hocher B; Kanasaki K; Haneda M; Schernthaner G; Sharma K; Stanton RC; Toto R; Cescutti J; Gordat M; Meinicke T; Koitka-Weber A; Thiemann S; von Eynatten M
Diabetes Obes Metab; 2017 Nov; 19(11):1610-1619. PubMed ID: 28636754
[TBL] [Abstract][Full Text] [Related]
8. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
Cherney DZI; Charbonnel B; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Shih WJ; Frederich R; Maldonado M; Pong A; Cannon CP;
Diabetologia; 2021 Jun; 64(6):1256-1267. PubMed ID: 33665685
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
Petrie JR; Chaturvedi N; Ford I; Brouwers MCGJ; Greenlaw N; Tillin T; Hramiak I; Hughes AD; Jenkins AJ; Klein BEK; Klein R; Ooi TC; Rossing P; Stehouwer CDA; Sattar N; Colhoun HM;
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):597-609. PubMed ID: 28615149
[TBL] [Abstract][Full Text] [Related]
10. Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis.
Talha KM; Green J; Filippatos G; Pocock S; Zannad F; Brueckmann M; Schueler E; Ofstad AP; Ferreira JP; Anker SD; Butler J; Rosenstock J; Packer M
Diabetes Obes Metab; 2024 Jul; 26(7):2578-2587. PubMed ID: 38558314
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria.
Delanaye P; Wissing KM; Scheen AJ
Clin Kidney J; 2021 Dec; 14(12):2463-2471. PubMed ID: 34950459
[TBL] [Abstract][Full Text] [Related]
12. Association of the longitudinal trajectory of urinary albumin/creatinine ratio in diabetic patients with adverse cardiac event risk: a retrospective cohort study.
Li H; Ren Y; Duan Y; Li P; Bian Y
Front Endocrinol (Lausanne); 2024; 15():1355149. PubMed ID: 38745945
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin after Acute Myocardial Infarction.
Butler J; Jones WS; Udell JA; Anker SD; Petrie MC; Harrington J; Mattheus M; Zwiener I; Amir O; Bahit MC; Bauersachs J; Bayes-Genis A; Chen Y; Chopra VK; Figtree G; Ge J; Goodman SG; Gotcheva N; Goto S; Gasior T; Jamal W; Januzzi JL; Jeong MH; Lopatin Y; Lopes RD; Merkely B; Parikh PB; Parkhomenko A; Ponikowski P; Rossello X; Schou M; Simic D; Steg PG; Szachniewicz J; van der Meer P; Vinereanu D; Zieroth S; Brueckmann M; Sumin M; Bhatt DL; Hernandez AF
N Engl J Med; 2024 Apr; 390(16):1455-1466. PubMed ID: 38587237
[TBL] [Abstract][Full Text] [Related]
14. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
Nishimura R; Tanaka Y; Koiwai K; Inoue K; Hach T; Salsali A; Lund SS; Broedl UC
Cardiovasc Diabetol; 2015 Jan; 14():11. PubMed ID: 25633683
[TBL] [Abstract][Full Text] [Related]
15. Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project).
Nielsen SF; Duus CL; Buus NH; Bech JN; Mose FH
JMIR Res Protoc; 2024 May; 13():e56067. PubMed ID: 38680116
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Häring HU; Merker L; Seewaldt-Becker E; Weimer M; Meinicke T; Woerle HJ; Broedl UC;
Diabetes Care; 2013 Nov; 36(11):3396-404. PubMed ID: 23963895
[TBL] [Abstract][Full Text] [Related]
17. Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial.
Gullaksen S; Vernstrøm L; Sørensen SS; Ringgaard S; Laustsen C; Funck KL; Poulsen PL; Laugesen E
Diabetologia; 2023 May; 66(5):813-825. PubMed ID: 36746803
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.
Dandona P; Chaudhuri A
Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28440009
[TBL] [Abstract][Full Text] [Related]
19. Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials.
Wanner C; Iliev H; Duarte N; Schueler E; Soares AR; Thanam V; Pfarr E
Adv Ther; 2024 May; ():. PubMed ID: 38771475
[TBL] [Abstract][Full Text] [Related]
20. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators.
Levin SR; Coburn JW; Abraira C; Henderson WG; Colwell JA; Emanuele NV; Nuttall FQ; Sawin CT; Comstock JP; Silbert CK
Diabetes Care; 2000 Oct; 23(10):1478-85. PubMed ID: 11023140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
